

UPDATE Executive Officer Notice: Reimbursement and Claim Submissions for Mifepristone / Misoprostol products

July 31, 2026

This is an update to an earlier [Executive Officer \(“EO”\) notice](#) dated April 23, 2026.

This notice provides information on updates to the Mifepristone / Misoprostol products. As the unit price of these publicly funded products follows the [pan-Canadian Tiered Pricing Framework](#), the price automatically reduces after 3 months of funding. Please refer to the [Ontario Drug Benefit \(ODB\) Formulary / Comparative Drug Index \(CDI\)](#) for the unit price. See updated Reimbursement Amounts as a result of the change in unit price in **Table 1**.

Since [August 2017](#), Ontario has publicly funded Mifegymiso® (mifepristone/misoprostol) for all Ontarians with:

- a valid Ontario health number, and
- a valid prescription.

Effective April 30, 2026, Femyso™ (mifepristone/misoprostol), a generic version of mifepristone/misoprostol, was designated as an Off-Formulary (OFI) interchangeable product with Mifegymiso® under the *Drug Interchangeability and Dispensing Fee Act* (DIDFA) and has been eligible for public funding in accordance with this EO notice.

Reimbursement Amount for Mifepristone/Misoprostol Products

For each valid claim for payment (“claim”) submitted in accordance with this EO notice, pharmacies are paid a professional service fee, which consists of the applicable drug cost (i.e., unit price) of the product dispensed, a mark-up on that price, and a dispensing fee. The total reimbursement amount for a valid claim is set out in Table 1 below.

Patient Eligibility

There have been no changes to patient eligibility for publicly funded mifepristone/misoprostol products. All Ontarians with a valid Ontario Health number and a valid prescription are eligible for publicly funded mifepristone/misoprostol products (“eligible patients”). This includes ODB-eligible and non-ODB-eligible recipients.

Pharmacy Eligibility and Documentation Requirements

All pharmacies with valid Health Network System (HNS) subscription agreements and that are connected to the HNS may submit claims for payment for supplying publicly funded mifepristone/misoprostol products to eligible patients. Pharmacists who have a religious or conscientious objection to mifepristone/ misoprostol products are required to comply with any policies or other professional expectations set out by the Ontario College of Pharmacists (OCP), such as the [Human Rights Policy](#).

Standard documentation requirements for prescriptions apply. Pharmacists must keep records consistent with their obligations under the *Pharmacy Act, 1991*, the *Drug and Pharmacies Regulation Act* (DPRA), and any further instructions provided by the OCP and the Ministry of Health (ministry).

For the purposes of post-payment verification and in accordance with O. Reg. 264/16 made under the DPRA if applicable, records must be maintained for the Retention Period, as defined in the [Ontario Drug Programs Reference Manual](#) as “a period of at least 10 years from the last recorded pharmacy service provided to the ODB recipient, or 10 years after the day on which the ODB recipient reached or would have reached the age of 18 years, whichever is longer”.

Pharmacy Billing Procedure

The mifepristone/misoprostol products listed in Table 1 below, when supplied to eligible patients and supported by a valid claim, are reimbursed by the ministry.

The Product Identification Numbers (PINs) that appear in the Product Description column of Table 1 below are used to differentiate between the publicly funded mifepristone/misoprostol products and will appear on the OFI to facilitate the interchangeability of the products.

The PINs in Table 1 below are to be used by pharmacies when submitting claims to the ministry. Each PIN is associated with a reimbursement amount that is paid for each valid claim. The reimbursement amount consists of the applicable drug cost (i.e., unit price) of the product dispensed, a mark-up on that price, and a dispensing fee.

The ministry will accept manual/ paper claims for publicly funded mifepristone/misoprostol products if there is a need to use three intervention codes.

Table 1:

PIN	Product Description (PIN)	Reimbursement amount as of July 31, 2026
09858391	Mifegymiso® (02444038)	\$191.4500
09858392	Femyso (02560569)	\$191.4500

ODB-Eligible Patients

When submitting a claim for an eligible patient who has ODB program coverage, pharmacies must follow the normal process for submitting claims on the HNS with the following additional information:

- Intervention code *PS : Professional Care Services*
- Product Identification Number (PIN): 09858391 or 09858392
- Valid Pharmacist ID
- Professional Fee: \$191.4500 (includes drug cost, mark-up and dispensing fee)

Non-ODB-Eligible Patients

When submitting a claim for an eligible patient who does not have ODB program coverage, pharmacies must submit the following information:

- Patient Gender: '*F*' = female; '*M*' = male; '*U*' = unknown
- Patient Date of Birth: YYYYMMDD
- Patient's Ontario Health number
- Intervention codes:
 - **PS: Professional Care Services**
 - **ML: Established eligibility coverage (i.e., 1 day of the Plan 'S' coverage)**
- Carrier ID: 'S'
- Product Identification Number (PIN): 09858391 or 09858392
- Valid Pharmacist ID
- Professional Fee: \$191.4500 (includes drug cost, mark-up and dispensing fee)

Ministry Policy

The original EO notice dated August 3, 2017, and any updates to the EO notice are a ministry policy that pharmacy operators must comply with under section 3.2 of the HNS Subscription Agreement for Pharmacy Operators.

Additional Information:

For pharmacies:

For billing inquiries, please call ODB Pharmacy Help Desk at: 1-800-668-6641

For all other Health Care Providers and the Public:

Please call ServiceOntario, Infoline at 1-866-532-3161 TTY 1-800-387-5559.

In Toronto, TTY 416-327-4282

All other inquiries regarding the policy should be directed to DrugProgramsDelivery@ontario.ca